Investors

Corporate Profile

Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Founded in 1996, the Company is publicly traded on the NASDAQ Global Market under the ticker symbol SBBP.

| (Common Stock)

Stock chart for: SBBP.O. Currently trading at $4.40 with a 52 week high of $6.24 and a 52 week low of $2.00.

Data provided by Nasdaq. Minimum 15 minutes delayed.

Press Releases

Strongbridge Biopharma plc Announces Closing of Transaction with Novo Nordisk to Transfer the Rights to MACRILEN™ (macimorelin) in the United States and Canada

12/19/18

Strongbridge Used Portion of $145 Million Upfront Cash Payment from Novo Nordisk to Fully Repay Outstanding Debt DUBLIN, Ireland and TREVOSE, Pa. , Dec. 19, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc , (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the...

Read More
Strongbridge Biopharma plc Announces Presentation of New Data Comparing the In Vitro Effects of Levoketoconazole, the Active Ingredient in RECORLEV™, and Ketoconazole on Human Cortisol Production

11/20/18

In Vitro Data Show Preliminary Evidence That Levoketoconazole Inhibits ACTH Secretion and May Have Anti-Tumor Effect on Pituitary Adenoma Cells First Study in Primary Human Adrenal Cells Suggests Levoketoconazole, the Pure 2S,4R Enantiomer of Ketoconazole, May Be a More Potent Inhibitor of Cortisol...

Read More

Investors

Investors

Corporate Profile

Press Releases

Strongbridge Biopharma plc Announces Closing of Transaction with Novo Nordisk to Transfer the Rights to MACRILEN™ (macimorelin) in the United States and Canada

Strongbridge Biopharma plc Announces Presentation of New Data Comparing the In Vitro Effects of Levoketoconazole, the Active Ingredient in RECORLEV™, and Ketoconazole on Human Cortisol Production

Upcoming Events